Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

| More on:
A smiling businessman in the city looks at his phone and punches the air in celebration of good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Imugene Ltd (ASX: IMU) shares are having a strong start to the session on Tuesday.

At the time of writing, the ASX 300 stock is up 11% to 4.9 cents.

Why is this ASX 300 stock jumping?

The catalyst for today's strong gain has been the release of a clinical trial update on its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial. It is evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA).

According to the release, a bile tract cancer patient in Imugene's Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission.

In addition, the ASX 300 stock confirms that its Bile Tract Cancer Expansion part of the trial has now cleared its first cohort. This follows the first three patients being evaluated for safety and experiencing no dose limiting toxicities (DLTs). Management notes that it is now open for full enrolment of up to 10 patients.

It has been a big 12 months for VAXINIA. The company highlights that it received FDA Fast Track Designation in November 2023 for the clinical program and its treatment of Bile Tract Cancer. This allows for closer cooperation with the US FDA to expedite the program and the subsequent approval process, including potential for accelerated approval and priority review.

This was then complemented by the receipt of Orphan Drug Designation from the US FDA for VAXINIA's treatment of Bile Tract Cancer in September, which provides a range of incentives in addition to seven years market exclusivity upon FDA approval.

Patent extension granted

Also potentially giving the ASX 300 stock a lift is news that it has been granted a patent extension in the United States.

Imugene has received a patent extension to 2040 from the US Patent and Trademark Office (USPTO) for patent application number 16/324,541. This patent protects its oncolytic virotherapy CF33, including VAXINIA (CF33-hNIS) and CHECKVacc (CF33-hNIS-antiPDL1)

Commenting on both developments, the ASX 300 stock's CEO, Leslie Chong, said:

Imugene receiving this patent extension to 2040 from the US patent office is a significant milestone for the CF33 family of oncolytic viruses. The US is the core healthcare market, and we are delighted to strengthen the patent life.

We're also very pleased to see the two-year milestone reached for the Bile Tract Cancer patient who has maintained a complete response in our MAST study. Most importantly this is an outstanding result for the patient given the limited treatment options available, but also demonstrates the excellent potential of the CF33 oncolytic virus for this and other cancer types. We continue to enroll into the bile tract cancer expansion of the MAST trial.

Should you invest $1,000 in Imugene Limited right now?

Before you buy Imugene Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Imugene Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a momentous day for ASX shares, with the index hitting another record...

Read more »

A woman in a bright yellow jumper looks happily at her yellow piggy bank representing bank dividends and in particular the CBA dividend
Broker Notes

3 reasons to buy Woolworths shares this month

Goldman Sachs thinks that now is the time to buy this retail giant.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
52-Week Highs

12 ASX ETFs at new 52-week highs this Thursday

Do you own any of these lucky ETFs?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
52-Week Highs

Here are 6 ASX 200 stocks at new 52-week highs today

These six stocks are at it again this Thursday.

Read more »

Happy young woman saving money in a piggy bank.
Share Market News

Everything you need to know about the latest CBA dividend

Australia's largest bank has just declared its latest dividend. Here's what you need to know.

Read more »

Multi-ethnic people looking at camera sitting at public place screaming, shouting and feeling overjoyed about their windfall, good news or sports victory.
Share Market News

ASX 200 strikes new record high

ASX mining stocks and debuting Sigma-Chemist Warehouse shares are soaring today.

Read more »

A woman wearing a yellow and white striped top and headphones plays excitedly with her phone.
Bank Shares

$167: Have CBA shares become a 'meme stock'?

CBA shares have hit yet another new record high this Thursday.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »